Schizophrenia – Epidemiology – Mature Markets

DRG Epidemiology's coverage of schizophrenia comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report both the incidence and lifetime prevalence of schizophrenia for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations, the number of drug-treatment opportunities at specific lines of therapy are forecast across the major mature pharmaceutical markets.

DRG Epidemiology's schizophrenia forecast will answer the following questions:

  • How will improvements in survival change the number of people living with a diagnosis of schizophrenia?
  • Of all people diagnosed with schizophrenia, how many in each country across the major mature pharmaceutical markets are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of schizophrenia over the forecast period?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graphical depiction of the patient flow between or within different disease states for the major mature pharmaceutical markets. These patient flow diagrams are provided at the regional level, but may be requested for any specific country or forecast year.

In addition to the total number of cases for each forecast year, DRG Epidemiology provides at least ten years of forecast data for the following schizophrenia subpopulations:

  • Diagnosed lifetime prevalent cases by cognitive effect status.
  • Diagnosed lifetime prevalent cases with comorbid depression.
  • Diagnosed lifetime prevalent cases with comorbid dementia.
  • Diagnosed lifetime prevalent cases with comorbid alcohol abuse.
  • Diagnosed lifetime prevalent cases by drug-treatment status.
  • Diagnosed lifetime prevalent cases by symptom status.

Note: Coverage may vary by country.

Table of contents

  • Schizophrenia - Epidemiology - Mature Markets
    • Introduction
      • Key Findings
      • Key Updates
      • Diagnosed Lifetime Prevalence of Schizophrenia per 1,000 Adults in 2020 and 2040
      • Relative Sizes of the Factors Contributing to the Trend in Diagnosed Lifetime Prevalent Cases of Schizophrenia over the Next 20 Years
      • Analysis of Diagnosed Lifetime Prevalent Cases by Cognitive Impairment Status
      • Analysis of Lifetime Prevalent Cases by Diagnosed and Drug-Treated Status in 2020
      • Number of Additional Diagnosed Lifetime Prevalent Cases of Schizophrenia Across the Countries Under Study Due to Trends in Risk or Survival in 2040
    • Epidemiology Data
    • Epidemiology Populations
      • Lifetime Prevalent Cases
      • Diagnosed Lifetime Prevalent Cases
      • Diagnosed Incident Cases
      • Cognitive Impairment Cases
      • Comorbid Depression
      • Comorbid Dementia
      • Comorbid Alcohol Abuse
      • Drug-Treated Lifetime Prevalent Cases
      • Symptom Status Cases
      • Lifetime DALYs Gained
    • Reference Materials
      • Literature Review
        • Studies Included in the Analysis of Schizophrenia
        • Studies Excluded from the Analysis of Schizophrenia
      • Risk/Protective Factors
        • Risk/Protective Factors for Schizophrenia
      • Bibliography
      • Glossary